Journal
BIOTECHNOLOGY JOURNAL
Volume 7, Issue 8, Pages 946-957Publisher
WILEY-BLACKWELL
DOI: 10.1002/biot.201100305
Keywords
Diagnostics; Disease classification; Systems biology; Translational bioinformatics
Funding
- NIH/NCI
- Roy J. Carver Young Investigator Grant
- Grand Duchy of Luxembourg-Institute for Systems Biology Consortium
- Camille Dreyfus Teacher-Scholar Program
- HHMI Pre-Doctoral Fellowship
- NIH Director's Early Independence Award [DW DP5OD009145]
Ask authors/readers for more resources
In the past 15 years, new omics technologies have made it possible to obtain high-resolution molecular snapshots of organisms, tissues, and even individual cells at various disease states and experimental conditions. It is hoped that these developments will usher in a new era of personalized medicine in which an individual's molecular measurements are used to diagnose disease, guide therapy, and perform other tasks more accurately and effectively than is possible using standard approaches. There now exists a vast literature of reported molecular signatures. However, despite some notable exceptions, many of these signatures have suffered from limited reproducibility in independent datasets, insufficient sensitivity or specificity to meet clinical needs, or other challenges. In this paper, we discuss the process of molecular signature discovery on the basis of omics data. In particular, we highlight potential pitfalls in the discovery process, as well as strategies that can be used to increase the odds of successful discovery. Despite the difficulties that have plagued the field of molecular signature discovery, we remain optimistic about the potential to harness the vast amounts of available omics data in order to substantially impact clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available